Although colorectal cancer and endometrial cancer risks are similar in MLH1 and MSH2 mutation carriers, overall risk for pancreatic cancer in germline mutation MSH2 was 0.5% (95% CI: 0.0–1.5%) by age 75. Here, MSH2 is linked to familial pancreatic carcinoma.